In Q1 2018, ISR surveyed 117 outsourcers at biopharmaceutical sponsors regarding the use and performance of a variety of clinical development outsourcing models. According to respondents using the Preferred Provider model, the most frequently experienced benefits of employing this model include Improved service provider relationships/deeper partnerships (mentioned by 60% of respondents) and Vendor consolidation (59% of respondents). The most oft-mentioned drawback is Lack of ultimate control (41% of respondents) with several others close behind. To learn more about this report, follow the link to the Clinical Development Outsourcing Models (3rd edition) report preview.

Originally posted at Pharmaceutical Online

View File